MedinCell SA MEDCL
EURONEXT · France · Health Technology
€23.44-0.66 (-2.74%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
MONTPELLIER, France, September 30, 2026--Regulatory News: Medincell's (Paris:MEDCL) Annual General Meeting will be held as scheduled today at 6:00 p.m. at the Company's headquarters.
MONTPELLIER, France, September 21, 2026--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY®, two treatments utilizing Medincell's proprietary BEPO® technology, licensed to Teva as SteadyTeq™. The findings were presented at Psych Congress 2026, held from September 15 to 19 in New Orleans, Louisiana.
MONTPELLIER, France, September 09, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation in the following September 2026 investor conferences by Dr Grace Kim, Chief Strategy Officer, U.S. Finance.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.